Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tarnished HALO For Targacept/AstraZeneca Nicotinic Receptor Modulator

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Targacept and AstraZeneca halted further development of their neuronal nicotinic receptor modulator AZD3480 for cognitive dysfunction in schizophrenia after the drug failed to meet its primary endpoint in the Phase II HALO trial, but a final decision on the compound will wait for an ongoing trial in attention-deficit/hyperactivity disorder

Related Content

Roche Snaps Up Memory, Gains CNS Drugs
AstraZeneca R&D: Aim Early To Cut Cycle Time, Build Phase II Pipeline





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts